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The Aβ peptide forms extracellular plaques associated with Alzheimer's disease. In addition to protein fibrils,
amyloid plaques also contain non-proteinaceous components, including glycosaminoglycans (GAGs). We
have shown previously that the GAG low-molecular-weight heparin (LMWH) binds to Aβ40 fibrils with a
three-fold-symmetric (3Q) morphology with higher affinity than Aβ40 fibrils in alternative structures, Aβ42
fibrils, or amyloid fibrils formed from other sequences. Solid-state NMR analysis of the GAG–3Q fibril complex
revealed an interaction site at the corners of the 3Q fibril structure, but the origin of the binding specificity
remained obscure. Here, using a library of short heparin polysaccharides modified at specific sites, we show
that the N-sulfate or 6-O-sulfate of glucosamine, but not the 2-O-sulfate of iduronate within heparin is required
for 3Q binding, indicating selectivity in the interactions of the GAG with the fibril that extends beyond general
electrostatic complementarity. By creating 3Q fibrils containing point substitutions in the amino acid sequence,
we also show that charged residues at the fibril three-fold apices provide the majority of the binding free
energy, while charged residues elsewhere are less critical for binding. The results indicate, therefore, that
LMWH binding to 3Q fibrils requires a precise molecular complementarity of the sulfate moieties on the GAG
and charged residues displayed on the fibril surface. Differences in GAG binding to fibrils with distinct
sequence and/or structure may thus contribute to the diverse etiology and progression of amyloid diseases.© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Introduction
Aggregation of proteins and peptides into amyloid
fibrils is responsible for more than 50 human diseases
[1]. One of the most well-documented amyloid
pathologies isAlzheimer's disease (AD), which results
from the extracellular deposition of fibrils formed from
the Aβ peptide, which ranges from 38 to 43 amino
acids in length, along with intracellular deposits of the
protein tau [2,3]. Amyloid plaques also contain an
assortment of accessory molecules including nucleic
acids [4], lipids [5], metal ions [6], and glycosamino-
glycans (GAGs) [7]. GAGs are linear sulfated poly-
saccharides, which include heparan sulfate (HS),Authors. Published by Elsevier Ltd. This
nses/by/4.0/).the structure of which varies between mammals and
between different tissues [8], including the brain [9],
and its less ubiquitous, but more homogeneous and
highly sulfated variant heparin. Heparin and its shorter
derivative, low-molecular-weight heparin (LMWH),
have been shown to interact with a variety of amyloid
proteins in vitro including amylin [10,11], α-synuclein
[12], transthyretin [13,14], β2-microglobulin [15,16],
gelsolin [17,18], tau [19,20], and Aβ40/42 [21,22].
There is also increasing evidence that heparin and
other GAGs may be active participants in the for-
mation of amyloid fibrils. Heparin has been shown
to accelerate fibril formation [21,23], enhance fibril
stability [24,25], and decreaseamyloid toxicity [26,27].is an open access article under the CC BY license (http://
J Mol Biol (2017) 429, 2449–2462
2450 Compatibility between GAGs and Aβ amyloid fibrilsAs a consequence, prevention of amyloid–GAG
interactions has been considered as an anti-amyloid
strategy [28–30]. In addition to heparin and HS, a
number of other natural GAGs have been identified in
extracellular amyloid plaques, including chondroitin
sulfate [31–33], dermatan sulfate [34], and keratan
sulfate [35], all ofwhich, like heparin andHS, comprise
sulfated disaccharide units. These sulfate groups are
proposed as a requirement for molecular recognition
via electrostatic interactions between the GAG and
basic amino acid side chains of binding partners [36].
However, few models of an amyloid–GAG structure
have been determined to date [37,38], leaving
unresolved the question of how GAGs recognize the
cross-β structure of amyloid. Studies of soluble
(non-amyloid) proteins bound to GAGs suggest
that there is a complex relationship between protein
binding and charge disposition, conformation, and
flexibility of the polysaccharide [39]. Indeed, a recent
survey of the primary sequences of 437 heparin
binding proteins confirmed that the notion of consen-
sus binding sequences can be disregarded [40].
Instead, the contacts between GAGs and proteins
typically comprise short, well-spaced positive (lysine
or arginine) or potentially positive (histidine) amino
acids and those capable of hydrogen bonding
(glutamine, asparagine) alternating with hydrophobic
residues. Similar complexity in relation to amyloid
fibrils may also be expected to occur, especially given
the array of different amyloid structures that have
recently been determined using solid-state NMR
(SSNMR) [41–44]. However, a systematic study of
the biochemical origins of GAG–amyloid binding has
yet to be reported. Here, we characterize LMWH–
amyloid interactions in molecular detail, employing a
unique (single) structure of Aβ40 fibrils determined by
Paravastu and colleagues [45], known as 3Q. Using
substitutions in LMWH and in the protein sequence,
we reveal a surprising specificity in binding, which is
dependent on the substitution pattern of the GAG and
the display of positive amino acid side chains in the
fibril three-dimensional structure.
Despite all amyloid fibrils sharing a cross-β archi-
tecture [2,46], amyloid structures can be highly varied,
with differences in the number, orientation, and
organization of the β-strands, even for fibrils formed
from the same sequence [2,41,47,48]. In previous
work, we showed that differences in amyloid se-
quence and structure can have a profound effect on
LMWH binding [37,49]. For example, LMWH binds
with different affinity to fibrils of Aβ40 with distinct
morphologies (3Q, 2A, and fibrils with mixed morphol-
ogy formed fromAβ40denovo; Fig. S1 and [37]), while
little binding is observed under the same conditions for
fibrils of Aβ42, Aβ16–22, and amylin (Fig. S1 and [37]).
Mapping the binding sites of 3Q fibrils for LMWH using
SSNMR revealed specific chemical shift perturbations
for residues, which lie at the apices of the 3Q fibril
structure, indicating that the fibril architecture itselfis important in dictating binding [37]. These findings
suggest that GAG–amyloid interactions may be more
specific than perceived hitherto, in which binding was
thought to be dominated by non-specific electrostatic
complementarity of the negatively charged GAG and
positively charged fibril surface or a simple linear
consensus sequence [50].
Given the common finding that LMWH co-localizes
with amyloid fibrils, we sought here to unravel the
determinants of the binding site of LMWH to Aβ40
fibrils of 3Q morphology by altering systematically
both the GAG and protein chemistries. The interac-
tions between an array of short heparin molecules
containing specific sulfate substitutions and Aβ40
sequence variants assembled by seeding into a 3Q
fibril morphology are characterized in detail using
in vitro binding assays, complemented by SSNMR.
The results reveal the importance of both the GAG
substituents and peptide sequence in determining
the specific interaction site of LMWH for 3Q fibrils
and rationalize why amyloid fibril–GAG interactions
are commonly observed in vitro and in vivo [51–53].Results
Forming Aβ40 3Q fibrils by seeded growth
To investigate LMWH–Aβ40 fibril interactions,
Aβ40 fibrils with the 3Q morphology were prepared
by seeded elongation of wild-type (WT) 3Q fibril
seeds (kindly provided by Tycko [45]), with Aβ40
monomers uniformly labeledwith 13C and 15N formed
by recombinant expression in Escherichia coli (Mate-
rials and Methods) [49,54]. Fibril formation was
monitored under quiescent growth conditions using
thioflavin T (ThT) fluorescence, and the morphology
of the resulting fibrils was assessed using negative
stain transmission electron microscopy (TEM). The
results showed clear evidence for seeded fibril growth
in which an immediate and rapid increase in ThT
fluorescence occurs upon the addition of seed under
the conditions employed (Fig. 1a). Negative stain
TEM revealed linear, unbranched fibrils (Fig. 1b),
although the fibril “twist” identified in Ref. [45] was
not discernible in our hands. SSNMR was used to
verify the formation of 3Q fibrils (Fig. 1c–f) [45,55].
Two-dimensional (2D) 13C–13C dipolar-assisted ro-
tational resonance (DARR) spectra showed sharp
and well-dispersed resonances, consistent with gen-
eration of a specific fibril structure [37,45,49] (Figs. 1c
and S2). Using these experiments, 95% of the Cα 13C
resonances could be assigned (Table S1), although
ambiguous 13C chemical shifts of the isoleucine side
chains were observed, as reported previously [55].
The chemical shifts obtained correspond closely to
previously published values for fibrils of 3Q morphol-
ogy [45,49,55] (Fig. 1d), consistent with the
Fig. 1. Aβ40 fibrils of 3Q morphology are produced by seeded growth. (a) Seeded growth 5% (v/v) of 3Q fibril seeds
with Aβ40 WT monomers (20 μM) monitored by ThT fluorescence. (b) TEM image of fibrils formed in panel A after 24 h.
The scale bar represents 200 nm. (c) Three regions of a 2D 13C–13C SSNMR spectrum (with 50-ms DARR mixing) of
Aβ40 fibrils prepared with 3Q seeding. The experimental spectrum (black) is overlaid with a simulated spectrum (red)
based on the reported 13C chemical shifts for the 3Q morphology [45]. (d) 13C Cα and Cβ chemical shifts measured from
the spectrum in panel C compared with previous published assignments by Paravastu and colleagues [45]. Error bars on
the current data represent ± half the line widths measured at half peak height, with an average of 1.07 ppm across the
entire sequence. (e) Structure of the 3Q model of Aβ40 (viewed down the fibril axis) based on SSNMR restraints (PDB ID:
2LMQ [45]), showing the previously determined LMWH binding sites (yellow pentagons). Circled regions highlight three
long-range couplings between residues observed in Ref. [44], which are diagnostic of the hairpin structure (H13–V40,
F19–V36) and of the quaternary packing arrangement in the 3Q morphology (I31–V39). (f) Regions of a 2D 13C–13C
SSNMR spectrum (200-ms DARR mixing) showing long-range F19–V36 and I31–V39 cross peaks. Spectra are shown in
Fig. S2 and assignments in Table S1.
2451Compatibility between GAGs and Aβ amyloid fibrilsproduction of fibrils of the 3Q type,with noevidence for
formation of other polymorphs or fibrils formedwithout
seeding, which give rise to broad resonances con-
sistent with sample heterogeneity [49]. Previously, 3Q
fibrils were shown to differ from other fibril morphol-ogies through a I31–V39 inter-peptide cross peak, in
addition to key intra-peptide cross peaks F19–I32,
F19–V36, and H13–V40 that are more generally
characteristic of the loop type structure [45] (Fig. 1e).
In accord with the 3Q morphology, cross peaks
2452 Compatibility between GAGs and Aβ amyloid fibrilsassigned to inter-peptide I31–V39 coupling (Fig. 1e, f,
top) and cross peaks assigned to intra-peptide
F19–V36 (Fig. 1e, f, bottom), H13–V40, and F19–I32
(Figs. 1e and S2) coupling were visible in our sample
of WT 3Q Aβ40 fibrils by SSNMR. These cross peaks
were previously identified and assigned in spectra of
selectively 13C-labeled 3Q fibrils ([45] Fig. 3). These
3Q-seeded Aβ40 fibrils were then used to carry out
an analysis of the factors involved in GAG–3Q fibril
binding described below.
Sulfate-specific and disaccharide
structure-selective interactions of 3Q fibrils
with modified heparins
LMWH binding to 3Q fibrils was first examined
from the perspective of the disaccharide units
from which heparin is composed (Fig. 2a). Although
several studies of GAG binding to amyloid proteins
have been performed to date [12,13,21,56], few
have investigated the specificity of the GAG struc-
ture on the binding affinity to its target protein [37,38].
Heparin contains alternating α-D-glucosamine andFig. 2. Modifications of heparin substituents affect binding to
dp18 with labeled sulfate groups. (b) List of modifications to t
shown in color. (c) Binding curves of modified heparins to 3Q
three replicates with standard deviation at each heparin conc
where binding was detected. The solid line, where applicable
function. Additional heparin variant binding data are shown inuronic acid substituents, with sulfate modifications
commonly at the 2-O position on α-L-iduronate and
the 2-(amino) and 6-O positions on D-glucosamine
(Fig. 2a). The removal of sulfate groups from heparin
and, in the case of N-sulfate (NS), its specific re-
placement by N-acetyl, can be achieved chemically,
producing a library of systematically modified heparin
polysaccharides with predominantly homogeneous
substitution patterns [57]. These modifications en-
able detailed exploration of the relationship between
charge content and structure of the GAG in deter-
mining affinity for 3Q fibrils.
Previous work demonstrated that heparin chains
above two disaccharide units (dp4) bind 3Q fibrils with
similar affinity, with a ΔG° binding of ca. 25 kJ/mol
[37]. To investigate the role of different heparin
substituents on 3Q binding, a series of modified
heparin molecules was created using polysaccha-
rides varying in length from 8 to 14 disaccharide units
(dp16–dp28) containing sulfate to hydroxide substitu-
tions at the 2-O-sulfate (2-OS) and/or 6-O-sulfate
(6-OS) positions, and/or a variety of substitutions
at the 2-NS position (removal of sulfate orthe 3Q fibril. (a) Structure of a heparin disaccharide unit of
he heparin structure based on panel A, with modifications
fibrils of Aβ40. Each data point represents the average of
entration. Bmax, Kd, and ΔG° binding values are reported
, was obtained by non-linear least-squares fitting of a Hill
Fig. S3 and Table S2.
2453Compatibility between GAGs and Aβ amyloid fibrilssubstitution with trifluoroacetyl; Fig. 2a–b). (Note that
the difference in GAG chain length of the modified
GAGs examined here does not affect binding affinity
[37].) While the importance of sulfate moieties in
amyloid–heparin binding has been noted previously
[51,58], analysis of the relative importance of individ-
ual groups in the affinity of this GAG for amyloid has
not been reported.
An in vitro assay was employed to measure the
binding affinity of the heparin variants to 3Q fibrils
[49]. In this assay, the concentration of GAG bound
to 3Q fibrils was quantified by pelleting GAG-bound
fibrils by centrifugation and determining the saccha-
ride content in the supernatant by enzymatic digestion
with heparinase II followed by quantification using UV
spectroscopy (Materials and Methods) [49]. Binding
curves were produced from three replicate experi-
ments, and the resulting data were fit using theHill equation to determine an apparent Kd of binding
(Figs. 2c, 3, and S3). This value was compared
with analysis of the binding of dp18 (WT) heparin to
3Q fibrils (Kd = 30 ± 10 μM, Fig. 2c-i) and used to
compute the difference in Kd and hence the ΔΔG°
binding for each GAG variant (Fig. 3a–b, Table S2;
Materials andMethods). As expected [37,59], removal
of all negative charges (2-deOS, 6-deOS, deNS NAc)
resulted in no detectable binding of the modified GAG
to 3Q fibrils (Fig. S3A). Similarly, the 6-deOS; 2-deOS,
6-deOS; 6-deOS deNS NAc; and deNS, COCF3
heparin variants failed to bind 3Q fibrils or bound
too weakly for a Kd to be determined (Figs. 2c-ii and
S3B–D, Table S2). These results mirror previous
findings [36] that have shown that electrostatic
interactions are important for GAG–amyloid binding.
Most interesting, however, was the finding that the
sulfate groups at each position differ in their effect onFig. 3. Summary of heparin vari-
ants binding to 3Q fibrils of Aβ40.
(a) Binding of 3Q fibrils to all modified
heparin constructs tested overlaid
for comparison. Solid lines indicate
heparin variants for which binding
could be determined. Dashed lines
indicate heparin variants that show
little to no binding to 3Q fibrils and
for which a Kd value could not be
determined. Lines were obtained
by non-linear least-squares fitting of
a Hill function. Colors correspond
to Fig. 2b. (b) Comparison of ΔΔG°
binding of modified heparins to 3Q
fibrils, relative to unmodified heparin
(dp18), shown in Fig. 2c-i. Asterisks
denote heparin variants that showed
little or no binding. Error bars depict
the standard deviation over three
replicate assays.
2454 Compatibility between GAGs and Aβ amyloid fibrils3Qbinding. For example, substitution of the 2-OSwith
hydroxyl (2-deOS) showed no detectable effect on
GAG binding (Fig. S3E), despite the documented
effect that this modification has on both the confor-
mation of the iduronate residue and the geometry of
the glycosidic linkage [57,60,61]. By contrast, removal
of the 6-OS (6-deOS) reduced affinity to such an
extent that binding could not be measured over the
concentration range tested (Fig. 2c-ii). While substi-
tution at the 2-OS iduronate position may alter the
orientation of the glycosidic linkage, as well as the
equilibrium of boat, chair, and skew-boat conforma-
tions in iduronate, substitution of the 6-OS glucos-
amine position alters the global heparin conformation
less dramatically [57,60,61]. Hence, the 6-OS, but not
the 2-OS, is required for heparin binding to 3Q fibrils.
A more complex picture emerges from substitution
of the glucosamine NS. Removal of this moiety
(deNS) resulted in a small decrease in binding affinity
(Kd = 54 ± 9 μM; Fig. S3F). Binding is decreased
more significantly if the NS is replaced with N-acetyl
(deNS NAc, Kd = 95 ± 9 μM; Fig. S3G). Surprisingly,
replacement of the NS with N-trifluoroacetyl (deNS
COCF3) eliminated binding (Fig. S3D). Substitution of
two sulfates produced an intermediate effect (2-deOS,
deNS NAc, Kd = 77 ± 7 μM; Fig. S3H), highlighting
the importance of specific sulfate moieties in the
binding affinity to Aβ40 3Q fibrils and possible com-
pensatory effects of the substitutions [62]. Taken
together (Fig. 3a–b), the results show that individual
sulfates contribute differently to 3Q–LMWH binding,
with the 6-OS being critical, the 2-OS playing a minor
role, and the NS group showing substitution-specific
effects, pointing to the glucosamine residue as par-
ticularly important for dictating binding affinity to 3Q
fibrils.
Binding of 3Q fibril mutants to LMWH reveals the
role of different residues in GAG binding
In order to assess the heparin-3Q fibril interaction
from the perspective of different amino acid side
chains in the fibril structure, single-residue substitu-
tion variants of Aβ40 were produced and assembled
into 3Q fibrils by elongation of WT 3Q seeds with
each monomer (Figs. 4a and S4). Substitutions were
selected in residues which exhibited significant
chemical shift differences upon LMWH binding
(≥0.4 ppm for Cα/β/γ), including R5, H6, H13, H14,
E22, S26, and I31; Table S3) [49]. Amino acid
substitutions implicated in familial AD (A2T [63], D7N
[64], A21G [65], E22Δ [66], and E22K [67]) and
residues with positively charged side chains predict-
ed to interact with LMWH (K16, K28) [68] were also
included. Neutral residues in regions distant to the
proposed heparin binding site were substituted as
controls (V18A, M35A, V36A; Table S3). In total,
residues that are located on the 3Q fibril apices, on
the fibril sides, and distant from the proposed bindingsite were assessed, providing good coverage across
the fibril structure. In each case, the ability of the
variant Aβ40 monomer to elongate 3Q fibril seeds
was verified by ThT fluorescence (Figs. 4a and S4).
Although differences in absolute fluorescence inten-
sity were detected between Aβ40 variants presum-
ably due to small structural changes that affect ThT
binding, all variants except M35A (Fig. S4N) showed
the ability to be seeded with 3Q fibrils and were
further analyzed for GAG binding. TEM verified
the presence of long, straight fibrils in all samples
following seeding (Figs. 4b and S5). To further
confirm the presence of 3Q morphology, SSNMR
was performed on a subset of variants (H6F, E22K,
I31T), all of which showed a characteristic cross
peak attributed to the close proximity of H13 and V40
side chains in the hairpin structure and also detected
in WT 3Q fibrils ([45], Fig. S6). The binding affinity of
LMWH for each fibril sequence was next analyzed
as described above. The results (Figs. 4c and 5a–c,
and S7; Table S4) showed that the 3Q variant fibrils
bind LMWH, with affinities that span values similar
to WT 3Q (S26A, Fig. 4c-iv; H14F, Fig. S7E; V36A,
Fig. S7 K; ΔΔG° binding b1.1 kJ/mol), to variants
with affinities that are reduced (R5A, Fig. S7C; H6F,
Fig. 4c-i; A21G, Fig. S7F; ΔΔG° binding N2.2 kJ/mol;
Fig. 5b, Table S4). The weak-binding residues
comprise the disordered N-terminal region in the 3Q
fibril structure and,with residuesK28and I31 that lie at
the start of β-strand 2 (K28A, Fig. S7I; I31T, Fig. S7 J;
ΔΔG° binding ~2.0 kJ/mol), form the “corners” of the
triangular fibril topology that have been predicted
previously based on chemical shift perturbations
to provide the epicenter of LMWH binding [37,49]
(Fig. 5a–c). Residues H13–K16 located in β-strand 1
form a positive “stripe” on the fibril exterior that has
been proposed to bind heparin [68]. However, these
residues show only moderate changes in ΔΔG°
binding (1.1–1.9 kJ/mol) when substituted individually
with neutral residues (H13F, H14F, K16A; Fig. 4c-ii
and iii, Fig. S7E), ruling out interaction of LMWH with
the sides of the 3Q fibrils as the dominant binding
surface. Interestingly, residue V36A, which is distant
from the proposed binding site (Figs. S7K and 5b–c)
also exhibits a small, but significant ΔΔG° binding
(1.1 kJ/mol). This may reflect minor changes in fibril
structure during elongation from WT 3Q seeds. Most
notably, substitutions in N-terminal residues (A2T,
R5A, H6F, D7N) result in N2 kJ/mol ΔΔG° binding
(Fig. 5b–c), supporting the view that GAG–3Q binding
involves a specific interface at the fibril “corners,”while
other positively charged regions, such as the “stripe”
along the fibril axis formed by the parallel in register
stacking of H14 and K16, play a relatively minor role.
These results suggest that 3Q–LMWH binding does
not simply result from non-specific electrostatic com-
plementarity, but instead relies on precise alignment
of positively charged residues with specific sulfate
moieties in the GAG itself.
Fig. 4. Binding of 3Q fibril variants H6F, K16A, H13F, and S26A to LMWH shows a range of binding free energies.
(a) ThT fluorescence confirms that 3Q seeds from WT Aβ40 can be used to seed fibril formation of Aβ40 variants. Seed
[5% (v/v)] was added to each monomeric variant at or near the start of incubation, as indicated by an arrow on each panel,
causing a rapid increase in fluorescence (red or blue). Each curve shown is a representative based on four replicates.
(b) TEM confirms the presence of fibrils after 24 h of seeded growth. (c) Binding curves of variant 3Q fibrils to LMWH
indicate a range of binding free energies. Each data point represents the average of three replicates (with standard
deviation) at each LMWH concentration. The solid line was obtained by non-linear least-squares fitting of a Hill function.
Additional binding data are found in Fig. S7 and Table S4. Colors of the panels correspond to the ΔΔG° binding gradient
used in Fig. 5.
2455Compatibility between GAGs and Aβ amyloid fibrilsDiscussion
Origins of a specific LMWH–3Q fibril interaction
The results described above provide a rationale for
the ubiquitous presence of GAGs in amyloid depositsand reveal that the interaction between LMWH and
3Q fibrils displays a specificity that extends beyond a
simple electrostatic model, involving precise interac-
tions between specific sulfates on the GAG and
positively charged residues on the fibril surface (the
“corners” of 3Q fibrils). This cluster of positive charges
in the amyloid fibril structure is absent in Aβ40 2A
Fig. 5. Single-substitution variants highlight the impor-
tance of the 3Q fibril “corners” in LMWH binding. (a) The
sequence of Aβ40 with the locations of strands and
substitution positions in the 3Q morphology shown. (Note
that recombinant Aβ40 contains an N-terminal methionine
residue at position 0.) (b) Comparison of ΔΔG° values
obtained from the binding assay for 3Q variants, relative
to WT 3Q fibrils, colored from smaller (blue) to larger
(red) changes in ΔΔG° binding. Error bars depict variation
in binding between three replicate assays. (c) The Aβ40
3Q fibril structure (from PDBID 2LMQ [45] with an added
disordered N-terminus) with substituted residues mapped
as space-filling models, colored as in parts A and B.
2456 Compatibility between GAGs and Aβ amyloid fibrilsfibrils and other fibril classes with linear arrangements
of β-strands, such as Aβ16–22, amylin, and the
recently described structures of Aβ42 fibrils [69,70],
rationalizing the previously identified lower binding
affinity of LMWH for these fibril types (Fig. S1) [37].
Such precise surface complementarity may explain
the fundamentally different binding affinity of GAGs
for amyloid fibrils formed from different protein se-
quences and even for different fibril structures formedfrom identical or very similar protein sequence variants
(Fig. S1) [37,49].
A heparin binding site has been mapped previ-
ously on Aβ40 fibrils formed de novo, which contains
a mixtures of different fibril structures, but nonethe-
less, it was shown to include residues H13, H14, and
K16 [68]. Despite the presumably optimal location of
H14 or K16 on the 3Q fibril “sides,” which produces
a “stripe” of positive charge along the fibril axis
seeming ideal for binding negatively charged GAGs,
independent individual substitutions of H13, H14,
and K16 in 3Q fibrils did not eliminate LMWH
binding, suggesting that the “corners” of 3Q fibrils
provide a binding site more optimized for interaction
with LMWH. In accord with these findings, a recent
survey of heparin binding proteins [40] revealed
that there is no “universal” heparin binding motif as
such. Rather, short points on the protein surface
comprising typically either a positively charged or
hydrogen bonding amino acid adjacent to a hydro-
phobic residue, distributed throughout a particular
protein sequence, act as GAG–protein interaction
sites, emphasizing the importance of structure in
protein–heparin binding. By characterizing variants
of both the heparin molecule and protein sequence
for the interaction between 3Q fibrils and LMWH,
we show here that binding is dominated by specific
residues and substituents on the GAG, notably
residues at the 3Q symmetry axis of the fibril and the
6-OS position of the polysaccharide. The 6-OS group,
shown here to be an important component of GAG
binding to Aβ40 3Q fibrils, has also been demonstrat-
ed as a sulfate-dependent regulator of the BACE-1
enzyme, an upstream effector of Aβ production [71].
Hence, as 6-deOS is a poor inhibitor of Aβ production
relative to 6-OS heparin, it exerts a double effect on
the aggregation cascade: enhancing Aβ formation
and limiting heparin binding to the resultant fibrils.
Thus, the importance of the 6-OS sulfate group in the
GAG has far-reaching consequences that may affect
AD manifestation and progression.
While the fibril types studied here are in vitro-
derived structures, fibrils with similar three-fold
symmetric morphologies have been found in vivo
[72] by elongation of plaque material taken from
the brain of a patient with AD with monomeric Aβ40.
This modeled structure is also 3-fold symmetric and
contains a cluster of charged amino acids involving
residues R5-D7 and S26-K28. From the experiments
presented here, we predict that this brain-derived
fibril morphology should also bind GAGs with an
affinity similar to that of 3Q fibrils. Recently, Qiang
and colleagues [41] characterized a more extensive
array of amyloid fibrils elongated from plaques in
patients with AD who manifested different disease
progression rates, symptoms, and plaque localiza-
tions. The resulting SSNMR spectra of these samples
extended using Aβ40 or Aβ42 monomers showed
several dominant fibril morphologies, suggesting that
2457Compatibility between GAGs and Aβ amyloid fibrilsfibril formation in vivomay result in a limited number of
fibril structures that differ in individuals with different
disease types and manifestations, paralleling other
reports of the analysis of amyloid extracted from
human tissue [48]. Interestingly, several of the
dominant Aβ fibril structures observed in vivo have
chemical shifts comparable to those of Aβ40 3Q
amyloid fibrils, providing a link between the binding
of GAGs to 3Q fibrils produced in vitro described
here to amyloid plaques within patients. The results
presented also indicate that not all amyloid fibrils will
bind heparin or partially desulfated heparin derivatives
with equal affinity, potentially explaining the different
GAG content in fibril plaques and different disease
progression between individuals [47,72]. It will be
interesting to see in the future whether different GAG
molecules co-localize within different amyloid plaques
and whether GAG content correlates with disease
phenotype and/or disease progression.
Additional clues about the nature of the com-
patibility between heparin and Aβ40 were gleaned
from the analysis of 16 unrelated crystal structures ofFig. 6. Rules for heparin–fibril binding. Crystal structures of
fragments ranging from dimers to hexamers were compiled a
protein and heparin. The structures were then rotated into a
of inertia of heparin in each case, with the origin at the cente
along the z-axis. (b) Cross-section view of the heparin molecu
atom. (c) The positions of amino acid residues within 4 Å of o
(2LMQ [45]) with acidic and basic residues shown in red and b
space of heparin.protein–heparin complexes, in which the GAG con-
formation and the proximity of the sulfate groups
to different residue types were examined (Fig. 6,
Table S5). All GAG ligands examined adopted an
approximately linear structure at the protein surface
with sulfate groups distributed along the principal (z)
axis of inertia with a separation of around 5 Å
(Fig. 6a). This separationmirrors the ~4.7-Å repeating
distance along the fibril long axis, and so it is
reasonable to propose that in the LMWH–3Q com-
plex, the GAG orientation is approximately parallel to
the fibril axis. When viewed down the principal axis,
the GAG ligands occupy a cross-sectional area of
130 Å2, and the sulfate groups cluster into five radial
positions (Fig. 6b). Hence heparin is capable of
forming ionic interactions with multiple protein sur-
faces, and indeed, such a multi-faceted interaction
is expected to confer extra stability on the complex.
Acidic and basic residues within Aβ are in closest
contact with the ligands and extend into the cross-
sectional space and typically within 4 Å of one ormore
sulfate groups, whereas non-polar/aromatic residues16 unrelated proteins (Table S5) containing bound heparin
nd any extraneous molecules were removed, leaving the
new reference frame corresponding to the principal axes
r of mass of heparin. (a) The distribution of sulfate groups
les in which each point represents the position of a sulfur
ne or more sulfate groups. (d) The structure of 3Q fibrils
lue, respectively. The circles represent the cross-sectional
2458 Compatibility between GAGs and Aβ amyloid fibrilsand Thr, Ser, and Met tend to be more peripheral
(Fig. 6c). Figure 6d illustrates the cross-sectional
area of heparin when mapped onto the heparin
binding site at the apices of the 3-fold symmetric 3Q
fibril structure. The model implies that heparin can
interact simultaneously with an interface formed by
the N- and C-termini of one monomer and a second
interface formed by the loop region of an adjacent
monomer. Furthermore, the interaction site within the
heparin cross-sectional space is occupied by acidic
and basic residues, allowing intimate contact with the
sulfate groups with polar hydrogen bonding residues
situated peripherally. Together, these features may
explain the uniquely high affinity of heparin for the
3Q morphology while, at the same time, rationalizing
the ubiquity of GAG–amyloid interactions observed
in vitro and in vivo [56,73].
A recent review by Kisilevsky et al. [74] posits
that one outstanding question in the amyloid field
is whether GAGs and other co-precipitating plaque
components are “associated factors” or “critical
components” of aggregation. Previous studies, along
with the work presented here, indicate that while
GAGs are not required for fibrillation of Aβ40 in vitro,
they alter the kinetics of amyloid fibril growth
[10,17,21,23], stabilize fibrils [24,25], alter toxicity
[52,73], and bind extensively and specifically to the
fibril surface [37,49], potentially competing for inter-
action with molecular chaperones [75,76], metal ions
[6,77], nucleic acids [78], and other components
known to associate with amyloid fibrils and to affect
amyloid formation [79,80]. GAGs should thus perhaps
be considered as “influential participants” in Aβ40
aggregation and deposition. In summary, the results
presented suggest a topologically focused model for
GAG–amyloid interactions and indicate that the
structural polymorphism exhibited by amyloid fibrils
both in vitro [45,55] and in vivo [41,72] may affect the
interactions of fibrils with key accessory molecules.
These co-factors, as a result, may play a significant
role in determining disease development, presenta-
tion, and progression.Materials and Methods
Expression and purification of Aβ40 and
its variants
Commercial E. coli strain BL21 (DE3) cells (Agilent)
were transformed with a pETSAC plasmid containing
the sequence for Aβ40 [54], and bacteria were grown
in minimal medium for 13C, 15N-labeled samples [37]
or LB media for unlabeled samples [54]. Cultures
were grown and Aβ40 purified as described previ-
ously [37,49]. An identical procedure was used for
purification of both labeled and unlabeled samples.
The resulting Aβ40 protein contains an additionalN-terminal methionine residue that has no effect on
the fibrillation of Aβ40 or the morphology of fibrils
formed [54]. Final protein concentrations were esti-
mated from UV absorption in 7 M guanidinium
chloride at 280 nm using an extinction coefficient of
1490 M−1 cm−1. Site-directed mutagenesis was per-
formed using a Q5 kit (NEB) to create each variant
of Aβ40. Substitutions were verified by plasmid
sequencing (Beckman-Coulter Genomics). All vari-
ants were expressed and purified as described for the
WT sequence.
Aβ40 3Q fibril preparation
3Q fibril seeds of Aβ40 were prepared by diluting
fibrils of the 3Q morphology [45] (a kind gift from
R. Tycko) to 5% (v/v) in seeding buffer [25 mM
NaH2PO4 (pH 7.5), 0.01% (w/v) NaN3] and sonicat-
ing for 5 s “on,” 45 s “off” for 3 cycles at amplitude
20% (approx. 3 J) to produce seeds. Lyophilized
monomeric Aβ40 (or variant) was added to the fibril
seeds to a concentration of 0.9 mg/mLand incubated
quiescently overnight at 25 °C. After 18 h, the fibrils
were sonicated for 5 s and incubated quiescently
at 25 °C for 1 week. Fibril growth was verified using
negative stain TEM.
Seeded fibril growth kinetics monitored by
ThT fluorescence
To ensure that 3Q fibrils were forming by seeded
elongation of 3Q fibril seeds, fibril growth was moni-
tored using 20 μM Aβ40 monomer in the presence
or absence of 5% (v/v) 3Q seeds in seeding buffer
containing 10 μM ThT. Samples were incubated
quiescently at 37 °C in a 96-well plate (Corning
3881) sealed with Star Seal polyolefin film (StarLabs)
on a Fluorostar OPTIMA plate reader (BMG Labtech).
Fluorescence was monitored continuously at an
excitation wavelength of 440 nm and emission wave-
length of 480 nm for a minimum of 3 days. Only
samples that clearly demonstrated seeded growth and
showed no evidence for spontaneous (unseeded)
assembly were taken forward for analysis of heparin
binding. E22 variants, which formed fibrils rapidly
under unseeded conditions, showed difference fluo-
rescence intensity and curve shape in unseeded
versus seeded samples as shown.
TEM
A 10-μL drop of fibril sample was applied to a
formvar/carbon-coated copper specimen grid (Agar
Scientific Ltd., Stansted, UK) The drop was blotted
with filter paper after 30-s incubation. The grid was
then washed with 2 × 10 μL of water and 10 μL of 2%
(w/v) aqueous uranyl acetate. A second drop of 10 μL
of 2% uranyl acetate was then applied to the grid and
incubated 30 s and then dried at room temperature.
2459Compatibility between GAGs and Aβ amyloid fibrilsGrids were examined in a JEOL JEM-1400 transmis-
sion electron microscope in the Astbury Biostructure
Laboratory.
SSNMR experiments
Following 1 week of quiescent growth at 25 °C,
5 mg total of 0.9 mg/mL fibrils was pelleted by
centrifugation at 50,000g for 1 h in an ultracentrifuge
(BeckmanCoulter) and the supernatant was removed.
The pellet was packed in its hydrated state into a
3.2-mm zirconia MAS rotor without further treatment
for analysis by SSNMR. 2D 13C–13C spectra were
recordedat 16.3 Twith a 3.2-mmHXYprobeoperating
in double-resonance mode and magic-angle spinning
at 14 kHz. The operating temperature was 4 °C.
Hartmann–Hahn cross-polarization was achieved
with a 2-ms contact time, and 100-kHz proton
decoupling with SPINAL-64 was applied during signal
acquisition. Spectra were recorded with either a 10-ms
or 50-ms mixing time during which the proton nutation
frequency was adjusted to the MAS frequency of
14 kHz to meet the DARR condition [81]. Typically,
480 increments were acquired in the indirect (t1)
dimension with 400–600 transients per increment, and
the total measurement time varied from 2 to 7 days
depending on the efficiency of rotor packing. Phase-
sensitive detection in the indirect dimensions was
achieved using the States-TPPI method. Chemical
shifts are expressed relative to tetramethylsilane. The
simulated 13C–13C spectrum based on previously
published chemical shifts was obtained using a C
program written specifically for this purpose.
Preparation of heparin molecules with
specific substitutions
Modified heparin derivatives were prepared and
characterized as described [57]. N-trifluoroacetyl hep-
arin was prepared from deNS heparin as reported and
sized via gel filtration [82]. Unmodified LMWH (approx.
dp18) was also purchased from Iduron (Cheshire, UK).
Purchased LMWHhad similar binding properties to 3Q
fibrils as in-house preparations of heparin of compa-
rable length [compare Fig. 2c-i (produced in-house)
and Fig. S7A (purchased)].
Quantitation of heparin binding to 3Q fibrils
In vitro binding assays of fibril–heparin binding
were performed by quantifying the amount of GAG
remaining unbound at different fibril–GAG concen-
tration ratios, as described previously [49]. In brief,
fibrils (25 μL of a monomer equivalent concentration
of 0.9 mg/mL) were pelleted by centrifugation at
14,000g for 30 min to separate fibrillar material from
residual monomers. The pellet containing the fibrils
was then resuspended in a 1- to 10-foldmolar excess
of heparin in seeding buffer in a total final volume of125 μL. An LMWH mass of 4650 Da was assumed
for calculations of saccharide concentration. The
sample was incubated at room temperature quies-
cently overnight. Samples were then centrifuged at
14,000g for 30 min to pellet the fibrils and associated
GAG, and the supernatant was removed and placed
in a clean Eppendorf tube and assayed for heparin
content. Saccharide concentration was quantified by
the addition of 25 μL of heparinase II (produced
in-house, according to Ref. [83]) in 20 mM Tris–HCl,
50 mM NaCl, 4 mM CaCl2, and 0.01% (w/v) BSA
(pH 7.5), which cleaves the glycosidic bond gener-
ating unsaturated uronic acid. The reaction was
incubated on a rotator at room temperature for 18 h
and quenched by the addition of 850 μL of 50 mM
HCl. Samples were prepared in parallel with heparin
alone (no fibril) as standards so as to account for any
differences in kcat of heparinase II for different GAG
substrates [62]. The uronic acid content was then
determined by measuring the absorbance at 232 nm
using an extinction coefficient of 5500 M−1 cm−1
[84]. Three replicates were assayed in parallel, and
bound heparin was determined by comparison to
replicates of heparin cleavage in the absence of
fibrils. Fibril alone (no GAG) and pellet washes were
also included in each set. An identical procedure was
used to quantify GAG binding to fibril variants and for
the heparin variants analyzed here. Binding curves
were fitted to the Hill equation:
θ ¼ L½ n= Kd þ L½ n
  ð1Þ
where θ is the fraction of Aβ bound to heparin, [L]
is the concentration of unbound heparin, n is Hill
coefficient (cooperative sites), and Kd is the dissoci-
ation constant. Each protein variant and modified
heparin variant was first fitted individually. For all
variants, the Hill coefficient fitted in this way was
3.0 ± 0.3. This value was then held constant, and
the data were refit over all variants to yield the Kd
values presented in all figures and tables. From
the difference in Kd values of GAG binding to WT
and variant fibrils, or the binding of LMWH and its
derivatives, ΔΔG° binding was calculated from:
ΔG° ¼ RT ln Kdð Þ
ΔΔG° ¼ ΔG °−ΔG °WTð Þ ð2Þ
whereR is the universal gas constant (8.315 J/mol K),
T is temperature (298 K), and Kd is calculated from
Eq. (1) to yield an apparent free energy of bindingΔG°.
This value is then subtracted from the free energy of
binding from WT 3Q fibrils to LMWH (or dp18) for the
change in apparent free energy of binding, ΔΔG°.
Molecular modeling
Using the structural model of residues 9–40 pre-
viously reported in 3Q fibrils (2lmq.pdb [45]) as
a starting point, a model of full-length Aβ40 was
2460 Compatibility between GAGs and Aβ amyloid fibrilsconstructed using Modeller v. 9.13 [85]. Scripts were
written to add the flexible N-terminal residues 1–8
missing from 2LMQ, preceded by an additional
Met produced by recombinant expression of the
peptide. Analysis of heparin–fibril complexes was
performed using a C program written specifically for
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